Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer
- Written by PR Newswire
![]() |
Highlights
- FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer
- Phase III trial design based on 64Cu SAR-bisPSMA data package, including positive results from the completed PROPELLER trial
- A total of 383 prostate cancer patients to take part in a pivotal, non-randomised, single-arm,...
Read more: Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer